Proteostasis Therapeutics Announces Positive Preliminary FDA Phase 1 Results
(By Glenford S Robinson)
Proteostasis Therapeutics, Inc. (NASDAQ: PTI), stock price skyrocketed 300% today, October 18, 2017 on positive Phase 1 study news from the Food and Drug Administration (FDA), which stated that the company’s proprietary doublet PTI-801 and PTI-808 cystic fibrosis research medicines have proven safe at the dosage level administered to research volunteers. The study volunteers consist of 20 to 100 individuals, which includes healthy people and those with the disease.
Proteostasis Therapeutics, Inc. (PTI) is a clinical stage biopharmaceutical company focused on developing therapies effective against cystic fibrosis (CF), a diseased caused by the dysfunctional processing of protein in the human body.
Armed with over 450 issued patents and a topnotch group of research scientists in technology, pharmaceuticals, and healthcare, PTI is confident that it can support its claim as the Inventor of Digital Medicine. In fact, a positive Phase 1 result of its cystic fibrosis research drug study is a strong indication that the company is capable of supporting such claim, as the undisputed Inventor of Digital Medicine.
The company claimed to be the Inventor of Digital Medicine, simply because it has developed a new category of pharmaceuticals that measures the effectiveness of medication treatment, help physicians in improving clinical outcomes and thus, help patients accomplish health goals.
Proteostasis Therapeutics plans to bring its new digital solution to healthcare providers by coordinating its efforts with leading health systems and pharmaceutical companies which will increase access to better insights, optimized therapies, and reduced costs.
© 2018 mstardom.com. Mstardom Finance does not provide investment advice. All rights reserved.
I am a Clinical Lab Scientist, entrepreneur, investor and trader (stocks and Forex). I enjoy writing and publishing articles online.